Medication-Attributable Adverse Events in Heart Failure Trials.

ABSTRACT:

Background

Initiation and up-titration of guideline-directed medical therapies (GDMTs) for heart failure with reduced ejection fraction (HFrEF) remains suboptimal, in part because of concerns regarding tolerability and adverse events (AEs).

Objectives

The authors sought to compare rates of AE in patients randomized to GDMT medication vs placebo in a meta-analysis of landmark cardiovascular outcomes trials.

Methods

The authors assessed rates of reported AE in 17 landmark HFrEF clinical trials across each class of GDMT in the placebo and intervention arms. The overall rates of AE for each drug class, the absolute difference in frequency in AEs between the placebo and intervention arms, and the odds of each AE according based on randomization strata were calculated.

R

SUBMITTER: Harrington J 

PROVIDER: S-EPMC10084875 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature